By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Medco Health Solutions will offer patients diagnosed with chronic myeloid leukemia a companion diagnostic test to assess their response to tyrosine kinase inhibitor, or TKI, therapy under an agreement with MolecularMD announced today.

MolecularMD's qRT-PCR BCR-ABL assay will be used to help physicians make treatment decisions and to monitor patients on TKI therapy, under the terms of the deal.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.